clinical trial · NCT07032662
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH·phase2·recruiting·n = 162
Chronic Inflammatory Demyelinating PolyneuropathyImeroprubartPlacebo
brief summary
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
started
Mar 18, 2025
primary completion
Aug 1, 2028
completion
May 1, 2030
last updated
Sep 10, 2026
detailed description
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Imeroprubart in adult participants with active CIDP.
official title
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol